Award
NIH Reporter #5F30HL172628-02
Therapeutic potential of CC-90009 for cystic fibrosis
Recipient
University of North Carolina Chapel Hill
Award Amount
$41,184.00
Ceiling
$41,184.00
Awarded
August 27, 2025
Identifier
5F30HL172628-02
The award supports research on CC-90009 as a potential therapy for cystic fibrosis, focusing on rescuing PTC-CFTR variants and reducing ENaC activity to improve lung function in CF patients.
Description
This project investigates the therapeutic potential of CC-90009, a thalidomide derivative drug, for treating cystic fibrosis (CF) by promoting ribosomal readthrough to rescue premature termination codon (PTC) CFTR variants and reducing epithelial sodium channel (ENaC) activity. The research aims to improve defective mucociliary transport in CF and other muco-obstructive lung diseases through preclinical models.